Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAVE: Pevonedistat + Azacitidine + Venetoclax in AML
NCT04172844Phase 1Terminated
- Sponsor
- Medical College of Wisconsin
- Start
- Jan 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of pevonedistat in acute myeloid leukemia (AML) (2 arms), sponsored by Medical College of Wisconsin. Primary endpoints: Recommended Phase 2 Dose at 28 days and Toxicity Profile. Started Jan 2020; status: terminated.
02
Drugs
pevonedistat
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT04172844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04172844.